Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Dupixent

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Worried About a Market Crash? Here Are 3 Stocks That ‘Big Short’ Star Michael Burry Loves Here.

Worried About a Market Crash? Here Are 3 Stocks That ‘Big Short’ Star Michael Burry Loves Here.

Here are three top stocks that the ‘Big Short’ star Michael Burry owns in Q2 of 2025. Are UNH, REGN, and LULU undervalued right now?

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

5 Non-Cyclical Stocks to Buy Now if You're Worried About a Recession

As surging inflation and energy prices foster recessionary fears, it could be wise to bet on non-cyclical stocks because they tend to outperform the broader market when economic growth slows. Given the inelastic demand for their companies’ products, we think the shares of United Parcel Service (UPS), British American Tobacco…

inkl

Read news from The Economist, FT, and more,
with one subscription

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

360,986 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play